NCT01998828

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Sierra Oncology LLC - a GSK company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.

Conditions

• Polycythemia Vera
• Essential Thrombocythemia

Interventions

Type	Name	Description
DRUG	Momelotinib	Momelotinib tablet administered orally once daily

Timeline

• Start date: 2014-02-19
• Primary completion: 2015-03-17
• Completion: 2015-05-07
• First posted: 2013-12-02
• Last updated: 2020-04-20

Locations

15 sites across 5 countries: United States, Australia, Canada, France, Germany